Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2022; 12(12):5330-5331. doi:10.7150/thno.74512 This issue Cite

Erratum

Local administration of liposomal-based Srpx2 gene therapy reverses pulmonary fibrosis by blockading fibroblast-to-myofibroblast transition: Erratum

Qi Wang1#, Juan Liu1#, Yinan Hu1,2, Ting Pan1, Yongjian Xu1, Jun Yu3, Weining Xiong4, Qing Zhou5✉, Yi Wang1✉

1. Department of Respiratory and Critical Care Medicine, Key Laboratory of Pulmonary Diseases of National Health Commission, Key Site of National Clinical Research Center for Respiratory Disease, Wuhan Clinical Medical Research Center for Chronic Airway Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Sciences and Technology, 1095 Jiefang Ave, Wuhan 430030, China.
2. Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, 100029, Beijing, China.
3. Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Sciences and Technology, 1095 Jiefang Ave, Wuhan 430030, China.
4. Department of Respiratory and Critical Care Medicine, Shanghai Key Laboratory of Tissue Engineering, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, 639 Zhizaoju Lu, Shanghai, 200011, China.
5. The Center for Biomedical Research, Tongji Hospital, Tongji Medical College, Huazhong University of Sciences and Technology, 1095 Jiefang Ave, Wuhan 430030, China.
#These authors contributed equally to this work.

✉ Corresponding author: Yi Wang (Tel: 86-27-8366-5562; E-mail: wangyitjmu.edu.cn), Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. Or Qing Zhou (Tel: 86 More

Citation:
Wang Q, Liu J, Hu Y, Pan T, Xu Y, Yu J, Xiong W, Zhou Q, Wang Y. Local administration of liposomal-based Srpx2 gene therapy reverses pulmonary fibrosis by blockading fibroblast-to-myofibroblast transition: Erratum. Theranostics 2022; 12(12):5330-5331. doi:10.7150/thno.74512. https://www.thno.org/v12p5330.htm
Other styles

File import instruction

Corrected-article in Theranostics, Volume 11, 7110

Citation styles

APA
Wang, Q., Liu, J., Hu, Y., Pan, T., Xu, Y., Yu, J., Xiong, W., Zhou, Q., Wang, Y. (2022). Local administration of liposomal-based Srpx2 gene therapy reverses pulmonary fibrosis by blockading fibroblast-to-myofibroblast transition: Erratum. Theranostics, 12(12), 5330-5331. https://doi.org/10.7150/thno.74512.

ACS
Wang, Q.; Liu, J.; Hu, Y.; Pan, T.; Xu, Y.; Yu, J.; Xiong, W.; Zhou, Q.; Wang, Y. Local administration of liposomal-based Srpx2 gene therapy reverses pulmonary fibrosis by blockading fibroblast-to-myofibroblast transition: Erratum. Theranostics 2022, 12 (12), 5330-5331. DOI: 10.7150/thno.74512.

NLM
Wang Q, Liu J, Hu Y, Pan T, Xu Y, Yu J, Xiong W, Zhou Q, Wang Y. Local administration of liposomal-based Srpx2 gene therapy reverses pulmonary fibrosis by blockading fibroblast-to-myofibroblast transition: Erratum. Theranostics 2022; 12(12):5330-5331. doi:10.7150/thno.74512. https://www.thno.org/v12p5330.htm

CSE
Wang Q, Liu J, Hu Y, Pan T, Xu Y, Yu J, Xiong W, Zhou Q, Wang Y. 2022. Local administration of liposomal-based Srpx2 gene therapy reverses pulmonary fibrosis by blockading fibroblast-to-myofibroblast transition: Erratum. Theranostics. 12(12):5330-5331.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use